(160) have demonstrated that CRISPR/Cas9-mediated YTHDF2 knockout can inhibit cell proliferation, induce G2/M phase cell cycle arrest, promote apoptosis, and increase the sensitivity of diffuse large B-cell lymphoma (DLBCL) to ibrutinib and venetoclax. This evidence concerns the gene YTHDF2 and diffuse large B-cell lymphoma.